Timothy E. Morey
Corporate Officer/Principal at University of Florida
Profile
Dr. Timothy E.
Morey, MD, is a Professor at University of Florida and a Principal at Kegonsa Capital Partners LLC.
He is on the Board of Directors at Nanomedex Pharmaceuticals, Inc.
He received his doctorate degree from the University of Florida.
Timothy E. Morey active positions
Companies | Position | Start |
---|---|---|
University of Florida | Corporate Officer/Principal | 24/11/2009 |
Former positions of Timothy E. Morey
Companies | Position | End |
---|---|---|
NanoMedex Pharmaceuticals, Inc.
NanoMedex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology NanoMedex Pharmaceuticals, Inc. develops formulation strategy to allow drugs that are only soluble in oil to be soluble in water. It offers offers Microfol, a micro emulsion formulation containing the generic active pharmaceutical ingredient propofol and two IIG listed excipients-sodium caprylate and poloxamer, which replaces the macro emulsion components of the reference listed drug and its generic equivalents. The company’s formulation is applied to drug classes, including chemotherapeutics, anesthetics, anti-infective, anti-inflammatories and arrythmics, immunosuppressants, and vitamins. NanoMedex Pharmaceuticals was founded by Donn M. Dennis, Nikolaus Gravenstein, Jerome H. Modell and Timothy E. Morey in 2002 and is headquartered in Middleton, WI. | Founder | - |
Training of Timothy E. Morey
University of Florida | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Private companies | 1 |
---|---|
NanoMedex Pharmaceuticals, Inc.
NanoMedex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology NanoMedex Pharmaceuticals, Inc. develops formulation strategy to allow drugs that are only soluble in oil to be soluble in water. It offers offers Microfol, a micro emulsion formulation containing the generic active pharmaceutical ingredient propofol and two IIG listed excipients-sodium caprylate and poloxamer, which replaces the macro emulsion components of the reference listed drug and its generic equivalents. The company’s formulation is applied to drug classes, including chemotherapeutics, anesthetics, anti-infective, anti-inflammatories and arrythmics, immunosuppressants, and vitamins. NanoMedex Pharmaceuticals was founded by Donn M. Dennis, Nikolaus Gravenstein, Jerome H. Modell and Timothy E. Morey in 2002 and is headquartered in Middleton, WI. | Health Technology |
- Stock Market
- Insiders
- Timothy E. Morey